As such , assignment of study treatment will not be blinded. Subjects will be randomized to Arm A ( CY/nivolumab/ipilimumab/GVAX pancreas vaccine followed by nivolumab/ipilimumab/CRS - 207 ) or Arm B (nivolumab/ipilimumab/ CRS - 207 ) in a 1:1 fashion using permuted blocks of varying sizes . 5 .